The DOI matches its Crossref record; 122 of the 135 references it cites were found in a registry or an index; 84 of the 164 sources its claims cite were checked for support.
A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Open accessAbstract
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the current treatment landscape and novel strategies for both alcohol withdrawal syndrome and AUD. Promising results, including the use of psychedelics alongside psychotherapy, noninvasive neural-circuit-based interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, have emerged from recent studies. While these advancements show potential, further research is crucial for a comprehensive understanding of their effectiveness. The clear shortage of approved medications and other treatment modalities underscores the pressing need for ongoing research. © 2024 by the authors.
Overview
CoChat Summary
## TL;DR
This narrative review surveys current and emerging treatments for alcohol withdrawal syndrome (AWS) and alcohol use disorder (AUD), emphasizing that benzodiazepines remain first-line for AWS while only three medications are FDA-approved for AUD: disulfiram, acamprosate, and naltrexone. It highlights promising but still emerging options, especially psychedelics with psychotherapy, noninvasive neural-circuit interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, while stressing that more clinical research is needed.
## Key findings
- AUD is described as a major public health problem, contributing to over 140,000 annual deaths, over 200 related diseases and health conditions globally, and 5.1% of the global disease burden; the paper also states that only 7% of U.S. adults with AUD receive adequate treatment and only 16% of those treated achieve abstinence.
- For AWS, benzodiazepines are the gold standard/first-line treatment; in one RCT of 198 patients, phenobarbital reduced ICU admissions from 25.0% to 8.0% versus placebo, and a meta-analysis of 12 studies/1,934 patients found no difference between phenobarbital and benzodiazepines on intubation, seizures, or hospital/ICU length of stay.
- For AUD, the paper reports FDA-approved options as disulfiram, acamprosate, and naltrexone; a meta-analysis of 53 studies found the number needed to treat for naltrexone was 12 to prevent return to heavy drinking, and a meta-analysis of 24 RCTs (6,915 participants) found acamprosate reduced the risk of any drinking and increased cumulative abstinence.
- Several emerging treatments showed promising signals: psilocybin plus psychotherapy produced a twofold reduction in heavy drinking with NNT 4.5 over 32 weeks; semaglutide case series reported a mean AUDIT score decrease of 9.5 points (p < 0.001) in 6 patients; and exenatide in an RCT of 127 participants did not reduce heavy drinking days overall but did reduce cue reactivity, with benefit in the subgroup with BMI > 30 kg/m².
## Methods
- Narrative review based on an electronic literature search of PubMed, Google Scholar, Cochrane Library, and ClinicalTrials.gov.
- Included clinical and animal trials, plus relevant systematic reviews, meta-analyses, and case reports published between 1 January 2013 and 1 January 2024; excluded editorials, expert opinions, and meeting abstracts.
- Search terms covered alcohol, alcohol use disorder, alcohol withdrawal syndrome, alcohol dependence, alcohol consumption, relapse, anti-craving, and treatment-related terms; the review also provides brief historical/background context for each modality.
## Limitations
- The paper explicitly notes that for several interventions, data are scarce or no recent clinical trials were identified (for example, ketamine for AWS, antipsychotics for AWS, GHB for AWS, CBT in recent AUD studies, PF-5190457, and others), so evidence is uneven across treatments.
- The review states that further research is crucial and that many findings are promising but not yet definitive, especially for emerging modalities such as psychedelics, neural-circuit interventions, PDE-4 inhibitors, and GLP-1 agonists.
- Evident from the text: this is a narrative review, not a systematic review or meta-analysis of its own, so the synthesis depends on heterogeneous prior studies and does not report a single pooled effect estimate across the full topic.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
84 Valid · 2 Not valid · 76 Not checked · 16 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is no specific preference for a particular benzodiazepine in the existing literature, highlighting the need for personalized medication selection, particularly considering factors like liver dysfunction [10].”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.1. Benzodiazepines for AWS
What the sources say
- Supportedcites [10] Amato, 2010, Benzodiazepines for alcohol withdrawal, Cochrane Database Syst. Rev. source
The Discussion (page not provided) says there is no strong evidence that particular benzodiazepines are more effective than others for alcohol withdrawal, which supports the attributed claim. The sentence’s recommendation to personalize selection, including for liver dysfunction, is the citing authors’ inference rather than a finding established by this passage. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Benzodiazepines are currently the first-line treatment for AWS [10].”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 1. Introduction
What the sources say
- Supportedcites [10] Amato, 2010, Benzodiazepines for alcohol withdrawal, Cochrane Database Syst. Rev. source
The Discussion (page not provided) explicitly refers to benzodiazepines’ “current status as first-line treatment for alcohol withdrawal syndrome.” The claim describes that status, not a claim that they are superior to every alternative. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In another retrospective study of 30 patients receiving ketamine adjunctively with a lorazepam infusion for severe alcohol withdrawal, significant decreases in lorazepam infusion rates were observed at 24 h after ketamine initiation.”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.2. Medications Other than Benzodiazepines for Alcohol Withdrawal Syndrome
What the sources say
- Supportedcites [25] Shah, 2018, Adjunctive Use of Ketamine for Benzodiazepine-Resistant Severe Alcohol Withdrawal: A Retrospective Evaluation, J. Med. Toxicol. source
The Abstract Methods describe a retrospective review of patients receiving ketamine adjunctively with a lorazepam infusion for severe alcohol withdrawal. The Abstract Results report 30 patients and a significant decrease in lorazepam infusion rates from baseline at 24 hours after ketamine initiation. The Results > Outcomes section cautions that the study could not determine whether ketamine caused the decrease; the citing sentence reports the observed decrease, not causation. (LLM, conf=0.95)
plainstates a causen = 30- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The study found that high-dose gabapentin was statistically superior but clinically similar to lorazepam in reducing alcohol withdrawal severity.”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.2. Medications Other than Benzodiazepines for Alcohol Withdrawal Syndrome
What the sources say
- Supportedcites [31] Myrick, 2009, A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal, Alcohol. Clin. Exp. Res. source
The Abstract Methods section reports that 100 people seeking outpatient treatment for alcohol withdrawal were randomized to double-blind gabapentin or lorazepam treatment. The Abstract Results section states that high-dose gabapentin was statistically superior but clinically similar to lorazepam in reducing withdrawal severity, measured by CIWA-Ar scores (p=0.009). No page numbers are available in our copy. (LLM, conf=0.95)
plainstates a causen = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The study measured the need for diazepam during withdrawal and found that 32.0% of patients on baclofen 60 mg/day required additional diazepam, compared to 72.0% on the placebo.”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.2. Medications Other than Benzodiazepines for Alcohol Withdrawal Syndrome
What the sources say
- Partly supportedcites [16] Crunelle, 2023, Baclofen during alcohol detoxification reduces the need for additional diazepam: A randomized placebo-controlled trial, Alcohol Alcohol. sourceExperimental — accuracy not yet measured
The Results report that 8 of 25 patients (32.0%) receiving baclofen 60 mg/day needed diazepam, compared with 13 of 18 (72.2%) receiving placebo. The claim matches the baclofen figure but gives the placebo figure as 72.0%, rather than the 72.2% reported in the Results. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
83 more claims · 46 with their cited sources checked
Create a free account to see all 178 claims and to verify the 6 references still open.
- It may state two separate claims as one. 76
- The quote only partly states this claim. 5
- Probably not a substantial claim. 15
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908
Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
Goldstein, R. Z., & Volkow, N. D. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3119 · Cited by 2,749 · cited 1×
“Furthermore, the ventral PFC network, encompassing the medial PFC, orbitofrontal cortex, insular cortex, and ventral anterior cingulate cortex, influences emotional processing and limbic arousal in addiction [105].”
BackgroundNeurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008 · cited 1×
“Animal models have shown that both ethanol intake and anticipation prompt dopamine release in the NAc, impacting the mesocorticolimbic system associated with craving, reward, and behavioral control [111].”
BackgroundStrafella, A. P., Paus, T., Barrett, J., & Dagher, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-j0003.2001 · Cited by 1,058
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 2×
“A large-scale meta-analysis, comprising 27 RCTs, found that acamprosate was effective in prolonging abstinence but did not reduce rates of binge drinking [51].”
BackgroundObesity and addiction: Neurobiological overlaps
Volkow, N. D., Wang, G. ‐., Tomasi, D., & Baler, R. D. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01031.x · Cited by 800
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711 · cited 1×
“Furthermore, the psilocybin group had three times higher chances of having no heavy drinking days and fewer alcohol-related adverse consequences compared to the diphenhydramine group [78].”
BackgroundThe impact of brief alcohol interventions in primary healthcare: a systematic review of reviews
O'Donnell, A., Anderson, P., Newbury-Birch, D., Schulte, B., Schmidt, C., Reimer, J., & Kaner, E. (2014) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt170 · Cited by 613 · cited 1×
“These interventions typically take 5 to 20 min and are recommended for all patients with risky alcohol use [116].”
Background
Research works printed but not linked: 1
- Kabat-Zinn, J. (2013). Full Catastrophe Living, Revised Edition: How to Cope with Stress, Pain and Illness Using Mindfulness Meditation, Hachette.
Cited by
Cuproptosis: unveiling a new frontier in cancer biology and therapeutics
Feng, Y., Yang, Z., Wang, J., & Hai, Z. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01625-7 · Cited by 98
Alcohol in Daily Products: Health Risks, Cultural Considerations, and Economic Impacts
Herdiana, Y. (2025) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s495493 · Cited by 29
Reiter, N., Otte, H. R., Dalhoff, K., et al. (2025) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.70046 · Cited by 6
Reiter, N., Dalhoff, K., Petersen, T. S., Andersen, C. U., Wamberg, C., Erikstrup Clausen, N., Itenov, T. S., & Meyhoff, C. S. (2026) · Clinical Toxicology · doi:10.1080/15563650.2026.2630024 · Cited by 5
Epigenetic Insights into Substance Use Disorder and Associated Psychiatric Conditions
Ngo, A. L., Ahmad, C. M., Alkhansari, N. G., Nguyen, L., & Zhang, H. (2025) · Complex Psychiatry · doi:10.1159/000544912 · Cited by 7
Metadata
- Authors
- Celik, M., Gold, M. S., & Fuehrlein, B.
- Affiliations
- New York Medical College (US)
- Washington University in St. Louis (US)
- Yale University (US)
- Corresponding author
- Gold, Mark S.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2024-03-20
- Volume
- 14
- Issue
- 3
- Pages
- 294
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC10969323
- OpenAlex
- W4392986055
- Cited by
- 25
- References
- 135
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 5
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- alcoholism, alcohol withdrawal, pharmacotherapy, psychedelics, psychotherapy, phosphodiesterase-4 inhibitors, GLP-1 receptor agonists, treatment gap, disease burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. https://app.cochat.ai/papers/10.3390/brainsci14030294
- The paper
- Celik, M., Gold, M. S., & Fuehrlein, B. (2024). A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. Brain Sciences. https://doi.org/10.3390/brainsci14030294
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
